Source: http://www.gazette.gc.ca/rp-pr/p1/2018/2018-12-15/html/notice-avis-eng.html
Timestamp: 2019-11-20 23:02:21
Document Index: 464599159

Matched Legal Cases: ['art 1', 'art 2', 'art 1', 'art 1', 'art 1', 'art 1']

Canada Gazette, Part 1, Volume 152, Number 50: GOVERNMENT NOTICES
Canada Gazette, Part I, Volume 152, Number 50: GOVERNMENT NOTICES
Whereas the substance calcium 2-ethylhexanoate (Chemical Abstracts Service [CAS] Registry No. 136-51-6) is specified on the Domestic Substances List; footnote a
Whereas the Minister of the Environment and the Minister of Health (the ministers) have conducted a screening assessment of calcium 2-ethylhexanoate under subsection 73(1) of the Canadian Environmental Protection Act, 1999 footnote b and, on March 25, 2017, published in the Canada Gazette, Part I, for a 60-day public comment period, the draft screening assessment;
And whereas the ministers suspect that the information concerning a significant new activity in relation to calcium 2-ethylhexanoate may contribute to determining the circumstances in which the substance is toxic or capable of becoming toxic within the meaning of section 64 of the Canadian Environmental Protection Act, 1999,
Therefore, notice is hereby given that the Minister of the Environment intends to amend the Domestic Substances List pursuant to subsection 87(3) of the Canadian Environmental Protection Act, 1999 to indicate that subsection 81(3) of that Act applies to any significant new activities relating to calcium 2-ethylhexanoate, as set out in this Notice.
The final screening assessment document for the substances may be obtained from the Canada.ca (Chemical Substances) website.
136-51-6 S′
1. In relation to the substance in Column 1, opposite to this section:
(a) the use of the substance in the manufacture of any of the following products, in such a manner that the substance is present in a concentration that is greater than 0.1% by weight:
(i) a consumer product to which the Canada Consumer Product Safety Act applies, other than paint or another surface coating material that dries to a solid film if the substance is present in the paint or surface coating material in a concentration that is less than or equal to 0.5% by weight,
(ii) a cosmetic, as defined in section 2 of the Food and Drugs Act;
(b) any activity involving the use of the substance in any of the following products in which the substance is present in a concentration that is greater than 0.1% by weight, if the total quantity of the substance involved in the activity during any one calendar year is greater than 10 kg:
2. Despite section 1, the use of the substance as a research and development substance or a site-limited intermediate substance as those expressions are defined in subsection 1(1) of the New Substances Notification Regulations (Chemicals and Polymers), or in a consumer product or cosmetic that is intended for export only is not a significant new activity.
(h) a summary of all other information or test data in respect of the substance that are in the possession of the person proposing the significant new activity, or to which they may reasonably be expected to have access, and that permit the identification of hazards of the substance to the environment and human health and the degree of environmental and public exposure to the substance;
(i) the identification of every other government agency, either outside or within Canada, that the person proposing the significant new activity has notified of the substance and, if known, the agency’s file number and the outcome of the assessment by the department or agency and, if any, the risk management actions in relation to the substance imposed by the department or agency;
(j) the name, civic and postal addresses, telephone number and, if any, fax number and email address of the person proposing the significant new activity and, if they are not resident in Canada, of the person resident in Canada who is authorized to act on their behalf;
4. The information above will be assessed within 90 days after the day on which it is received by the Minister.
The Notice of Intent (NOI) is an opportunity for the public to comment on the proposed amendment to the Domestic Substances List (DSL) to apply the Significant New Activity (SNAc) provisions of the Canadian Environmental Protection Act, 1999 (CEPA) footnote 1 to the substance hexanoic acid, 2-ethyl-, calcium salt (also known as calcium 2-ethylhexanoate, Chemical Abstracts Service [CAS] Registry No. 136-51-6), pursuant to subsection 87(3) of that Act.
Information-gathering methods other than the use of the SNAc provisions were considered, including adding the substance to voluntary or mandatory surveys under CEPA, reporting to the National Pollutant Release Inventory, and the periodic market surveillance of products through the analysis of safety data sheets (SDS). footnote 2 However, these tools would collect information after the substance may have been used in products available to consumers, which could potentially lead to exposures of concern.
It is proposed that the Order amending the DSL require any person (individual or corporation) engaging in a significant new activity in relation to calcium 2-ethylhexanoate to submit a significant new activity notification (SNAN) containing all of the information prescribed in the Order at least 90 days prior to the import, manufacture, or use of the substance for the significant new activity.
For any other activity related to consumer products and cosmetics other than a paint and a coating, notification would be required when the concentration of the substance in the product is greater than 0.1% by weight, and the total quantity of the substance in the product that is used during a calendar year is greater than 10 kg. For any other activity in relation to a paint or coating, notification would be required when the concentration of the substance in the paint or coating is greater than 0.5% by weight and the total quantity of the substance in the product that is used during a calendar year is greater than 10 kg.
For example, notification would be required if a company plans to import a product to be used by consumers that is not a paint or coating where the concentration of the substance in the product is greater than 0.1% by weight and there is more than 10 kg of the substance involved in a calendar year. Examples of products of concern would include, but would not be limited to, cosmetics and do-it-yourself products such as sealants. Therefore, the import, manufacture, or use of the substance for such products as defined in the Order would require notification. Calcium 2-ethylhexanoate is known to be currently used in paints in Canada at concentrations below 0.5% by weight.
The proposed Order would not apply to products to which the CCPSA does not apply such as food and drugs, with the exception of cosmetics within the meaning of section 2 of the Food and Drugs Act. It would also not apply to uses of the substance that are regulated under the Acts of Parliament listed in Schedule 2 of CEPA, including the Pest Control Products Act, the Fertilizers Act and the Feeds Act. The Order would also not apply to transient reaction intermediates, impurities, contaminants, partially unreacted intermediates or in some circumstances to items such as wastes, mixtures or manufactured items. However, it should be noted that individual components of a mixture may be subject to notification under the Order. See subsection 81(6) and section 3 of CEPA and section 3 of the Guidelines for the Notification and Testing of New Substances: Chemicals and Polymers for additional information on the activities and conditions described above.
The use of calcium 2-ethylhexanoate as a research and development substance, a site-limited intermediate substance, or to manufacture an export-only product would not require the submission of a SNAN, as these activities are not expected to result in exposure to the general population in Canada. The terms “research and development substance” and “site-limited intermediate substance” are defined in subsection 1(1) of the New Substances Notification Regulations (Chemicals and Polymers). An export-only product manufactured with the substance is one destined solely for foreign markets.
The NOI sets out the proposed requirements for information that would have to be provided to the Minister 90 days before the day on which the substance is imported, manufactured or used for a significant new activity. The Department of the Environment and the Department of Health will use the information submitted in the SNAN and other information to conduct human health and environmental assessments within 90 days after the complete information is received.
When assessing whether or not a substance is subject to SNAc provisions, footnote 3 a person is expected to make use of information in their possession or to which they may reasonably be expected to have access. This means information in any of the notifier’s offices worldwide or other locations where the notifier can reasonably have access to the information. For example, manufacturers are expected to have access to their formulations, while importers or users of a substance, mixture, or product are expected to have access to import records, usage information and the relevant safety data sheets (SDS).
If any information becomes available that reasonably supports the conclusion that the substance calcium 2-ethylhexanoate is toxic or capable of becoming toxic, the person who is in possession of or has knowledge of the information, and is involved in activities with the substance is obligated, under section 70 of CEPA, to provide that information to the Minister without delay.
Where a person has questions concerning their obligations to comply with an order, believes they may be out of compliance, or would like to request a PNC, they are encouraged to discuss their particular circumstances by contacting the Substances Management Information Line. footnote 4
CEPA is enforced in accordance with the publicly available Compliance and Enforcement Policy for the Canadian Environmental Protection Act, 1999. In instances of non-compliance, consideration is given to the following factors when deciding which enforcement measure to take: nature of the alleged violation, effectiveness in achieving compliance with CEPA and its regulations and consistency in enforcement.
Whereas the 14 substances set out in this Notice are specified on the Domestic Substances List; footnote c
Whereas the Minister of the Environment and the Minister of Health (the ministers) have conducted rapid screening assessments of each of the 14 substances set out in this Notice under section 68 or 74 of the Canadian Environmental Protection Act, 1999 footnote d and, on October 27, 2018, published in the Canada Gazette, Part I, the final screening assessment report;
And whereas the ministers suspect that the information concerning a significant new activity in relation to any of the 14 substances set out in this Notice may contribute to determining the circumstances in which these substances are toxic or capable of becoming toxic within the meaning of section 64 of the Canadian Environmental Protection Act, 1999,
Therefore, notice is hereby given that the Minister of the Environment intends to amend the Domestic Substances List pursuant to subsection 87(3) of the Canadian Environmental Protection Act, 1999 to indicate that subsection 81(3) of that Act applies to any significant new activities relating to the 14 substances, as set out in this Notice.
The rapid screening assessment report for the 14 substances may be obtained from the Canada.ca (Chemical Substances) website.
74-88-4 S′
98-88-4 S′
100-00-5 S′
101-90-6 S′
118-96-7 S′
121-14-2 S′
126-99-8 S′
271-89-6 S′
556-52-4 S′
630-20-6 S′
632-99-5 S′
2475-45-8 S′
68953-80-0 S′
1. In relation to any substance in Column 1, opposite to this section:
(b) any activity involving the use of the substance in the following products, containing the substance at a concentration equal to or greater than 0.1% by weight, if the total quantity of the substance involved in the activity during any one calendar year is greater than 10 kg:
(i)	a consumer product to which the Canada Consumer Product Safety Act applies, or
(ii)	a cosmetic, within the meaning of section 2 of the Food and Drugs Act;
2. Despite item 1, the use of the substance as a research and development substance or as a site-limited intermediate substance as these expressions are defined in subsection 1(1) of the New Substances Notification Regulations (Chemicals and Polymers), or in a consumer product that is intended for export only is not a significant new activity.
(h) a summary of all other information and test data in respect of the substance that are in the possession of the person proposing the significant new activity, or to which they may reasonably be expected to have access, and that permit the identification of hazards to the environment and human health and the degree of environmental and public exposure to the substance;
(j) the name, civic and postal addresses, telephone number and, if any, fax number and email address of the person proposing the significant new activity and, if they are not resident in Canada, of the person resident in Canada who is authorized to act on their behalf; and
(k) a certification stating that the information is accurate and complete, dated and signed by the person proposing the significant new activity, if they are resident in Canada or, if not, by the person resident in Canada who is authorized to act on their behalf.
4. Part 2 of the Domestic Substances List is proposed to be amended by adding the following in numerical order:
95-54-5 S’
(a) the use of the substance in the manufacture of a consumer product to which the Canada Consumer Product Safety Act applies that contains the substance at a concentration greater than 0.1% by weight; or
(b) any activity involving the use of the substance in a quantity greater than 10 kg in a calendar year in a consumer product to which the Canada Consumer Product Safety Act applies that contains the substance at a concentration greater than 0.1% by weight.
(e) a description of the consumer product that contains the substance, the concentration of the substance in the consumer product, the intended use of that consumer product and the function of the substance in that consumer product;
(g) the total quantity of the consumer product expected to be sold in Canada in a calendar year by the person proposing the significant new activity;
(j) the name, civic and postal addresses, telephone number and, if any, the fax number and email address of the person proposing the significant new activity and, if they are not resident in Canada, of the person resident in Canada who is authorized to act on their behalf; and
(k) a certification that the information is accurate and complete, dated and signed by the person proposing the significant new activity, if they are resident in Canada or, if not, by the person resident in Canada who is authorized to act on their behalf.
5. This Order would come into force on the day on which it is registered.
The Notice of Intent (NOI) is an opportunity for the public to comment on the proposed amendments to the Domestic Substances List (DSL) to apply the Significant New Activity (SNAc) provisions of the Canadian Environmental Protection Act, 1999 (CEPA) footnote 5 to the 14 substances listed in Table 1, pursuant to subsection 87(3) of that Act.
Within 60 days of publication of the NOI, any person may submit comments to the Minister of the Environment. These comments will be taken into consideration during the development of the Order amending the DSL to apply the SNAc provisions to the 14 substances listed in Table 1.
Information-gathering mechanisms other than the SNAc provisions of CEPA were considered, including the publication of a notice under section 71 of CEPA, and additions to monitoring and biomonitoring programs. However, these tools would collect information after the substance may have been used in products, including cosmetics, available to consumers, which could potentially lead to exposures of concern.
At this time, it is proposed that the Order amending the DSL require any person (individual or corporation) engaging in a significant new activity in relation to any of the 14 substances listed in Table 1 to submit a significant new activity notification (SNAN) containing all of the information prescribed in the Order at least 90 days prior to the import, manufacture or use of the substance for the significant new activity.
To address human health concerns, the Order would target the use of the substances listed in Table 1 in consumer products to which the Canada Consumer Product Safety Act (CCPSA) applies, as well as in cosmetics (with the exception of 1,2-benezenediamine [Chemical Abstracts Service Registry Number (CAS RN) 95-54-5]), as these are defined in section 2 of the Food and Drugs Act (FDA). Consumer products and cosmetics are potential sources of direct and significant human exposure to these substances. For the manufacture of such products with the substance, notification would be required when the concentration of the substance in the consumer product or cosmetic is equal to or greater than 0.1% by weight.
For any other activity related to the substance in consumer products or cosmetics, notification would be required when the concentration of any substance listed in Table 1 in the consumer product or cosmetic is 0.1% by weight or more, and the total quantity of the substance involved in the activity during a calendar year is greater than 10 kg. For example, notification would be required if a company planned to import a product to be used by consumers where the concentration of the substance in the product were 0.1% or greater by weight, and where there were more than 10 kg of the substance involved in a calendar year. The import, manufacture, or use of the substance in such products would require notification.
In relation to the substances listed in Table 1, the manufacture of consumer products or cosmetics that contain any of the substances at a concentration less than 0.1% by weight would be excluded from the application of the proposed Order. Similarly, any other activity involving the substance in a consumer product or a cosmetic would not be subject to the Order if the total quantity of the substance involved in the activity is 10 kg or less in a calendar year. For activities involving more than 10 kg of the substance in a calendar year, the Order would not apply if the concentration of the substance in the consumer product or cosmetic involved in the activity is less than 0.1% by weight for each substance. Activities relating to the use of 1,2-benezenediamine (CAS RN 95-54-5) in cosmetics would also not be subject to the Order as the substance is identified on Health Canada’s Cosmetic Ingredient Hotlist as prohibited for use in cosmetic products sold in Canada.
The proposed Order would not apply to uses of these substances that are regulated under the Acts of Parliament listed in Schedule 2 of CEPA, including the Pest Control Products Act, the Fertilizers Act and the Feeds Act. The Order would also not apply to transient reaction intermediates, impurities, contaminants, or partially unreacted intermediates, or in some circumstances to items such as wastes, mixtures or manufactured items. However, it should be noted that individual components of a mixture may be subject to notification under the Order. See subsection 81(6) and section 3 of CEPA, and section 3 of the Guidelines for the Notification and Testing of New Substances: Chemicals and Polymers for additional information.
The use of the substance as a research and development substance, a site-limited intermediate substance, or in a consumer product intended for export-only would not require the submission of a SNAN as these activities are not expected to result in exposure to the general population in Canada. The terms “research and development substance” and “site-limited intermediate substance” are defined in subsection 1(1) of the New Substance Notification Regulations (Chemicals and Polymers). A consumer product that is intended for export-only is one that is manufactured or imported in Canada and destined solely for foreign markets.
The NOI sets out the proposed requirements for information that would have to be provided to the Minister 90 days before the day on which the substances are imported, manufactured or used for a significant new activity. The Department of the Environment and the Department of Health will use the information submitted in the SNAN and other information to conduct human health and environmental assessments within 90 days after the complete information is received.
The information requirements in the proposed Order relate to general information in respect of the substances, to details surrounding their use, and to exposure information. Some of the proposed information requirements are set out in the New Substances Notification Regulations (Chemicals and Polymers).
When assessing whether or not a substance is subject to SNAc provisions, footnote 6 a person is expected to make use of information in their possession or to which they may reasonably be expected to have access. This means information in any of the notifier’s offices worldwide or other locations where the notifier can reasonably have access to the information. For example, manufacturers are expected to have access to their formulations, while importers or users of a substance, mixture, or product are expected to have access to import records, usage information and the relevant safety data sheet (SDS). footnote 7
If any information becomes available that reasonably supports the conclusion that any of the substances identified in this proposed Order is toxic or capable of becoming toxic, the person who is in possession or has knowledge of the information and is involved in activities with the substance is obligated, under section 70 of CEPA, to provide that information to the Minister without delay.
A company can submit a SNAN on behalf of its clients. For example, in cases where a person takes possession and control of a substance from another person, they may not be required to submit a SNAN, under certain conditions, if their activities were covered by the original SNAN. The Substances Management Advisory Note, “Clarification in relation to the submission of Significant New Activity Notifications in application of the Canadian Environmental Protection Act, 1999,” provides more detail on this subject.
Where a person has questions concerning their obligations to comply with a notice or order, believes they may be out of compliance, or would like to request a PNC, they are encouraged to discuss their particular circumstances by contacting the Substances Management Information Line. footnote 8
Therefore, the Minister of the Environment, pursuant to subsection 87(5) of the Canadian Environmental Protection Act, 1999footnote a, makes the annexed Order 2018-87-07-02 Amending the Non-domestic Substances List.
Gatineau, December 4, 2018
1 Part I of the Non-domestic Substances List footnote 9 is amended by deleting the following:
2 This Order comes into force on the day on which Order 2018-87-07-01 Amending the Domestic Substances List comes into force.
Publication of final decision after screening assessment of two substances — hexanoic acid, 2-ethyl-, calcium salt (calcium 2-ethylhexanoate), CAS RN 1 136-51-6, and hexanoic acid, 2-ethyl-, 2-ethylhexyl ester (2-ethylhexyl 2-ethylhexanoate), CAS RN 7425-14-1 — specified on the Domestic Substances List (paragraphs 68(b) and (c) or subsection 77(6) of the Canadian Environmental Protection Act, 1999)
Whereas calcium 2-ethylhexanoate is a substance identified under subsection 73(1) of the Canadian Environmental Protection Act, 1999; footnote 10
Whereas a summary of the final screening assessment conducted on 2-ethylhexyl 2-ethylhexanoate pursuant to paragraphs 68(b) and (c) of the Act and on calcium 2-ethylhexanoate pursuant to section 74 of the Act is annexed hereby;
Whereas it is concluded that 2-ethylhexyl 2-ethylhexanoate meets one or more of the criteria set out in section 64 of the Act;
And whereas it is concluded that calcium 2-ethylhexanoate does not meet any of the criteria set out in section 64 of the Act,
Notice is hereby given that the Minister of the Environment and the Minister of Health (the ministers) propose to recommend to Her Excellency the Governor in Council that 2-ethylhexyl 2-ethylhexanoate be added to Schedule 1 to the Act.
Notice is furthermore given that the ministers have released a risk management approach document for 2-ethylhexyl 2-ethylhexanoate to continue discussions with stakeholders on the development of risk management actions.
Notice is furthermore given that the ministers propose to take no further action on calcium 2-ethylhexanoate at this time under section 77 of the Act.
Notice is also hereby given that the Minister of the Environment intends to amend the Domestic Substances List pursuant to subsection 87(3) of the Canadian Environmental Protection Act, 1999 to indicate that subsection 81(3) of that Act applies with respect to calcium 2-ethylhexanoate.
Summary of the final screening assessment of calcium 2-ethylhexanoate and 2-ethylhexyl 2-ethylhexanoate
Pursuant to sections 68 and 74 of the Canadian Environmental Protection Act, 1999 (CEPA), the Minister of the Environment and the Minister of Health have conducted a screening assessment of calcium 2-ethylhexanoate and 2-ethylhexyl 2-ethylhexanoate. These substances were identified as priorities for assessment, as they met the categorization criteria under subsection 73(1) of CEPA or were considered a priority on the basis of other human health concerns. Their Chemical Abstracts Service Registry Numbers (CAS RNs), their Domestic Substances List (DSL) names and their common names are listed in the table below.
136-51-6 Hexanoic acid, 2-ethyl-, calcium salt Calcium 2-ethylhexanoate
7425-14-1table 1 note a Hexanoic acid, 2-ethyl-, 2-ethylhexyl ester 2-Ethylhexyl 2-ethylhexanoate
This substance was not identified under subsection 73(1) of CEPA, but was included in this assessment as it was considered as a priority on the basis of other human health concerns.
In 2011, there were no reports of manufacture of calcium 2-ethylhexanoate above the reporting threshold of 100 kg, but between 10 000 and 100 000 kg of calcium 2-ethylhexanoate were imported into Canada. There were no reports of manufacture or import of 2-ethylhexyl 2-ethylhexanoate above the reporting threshold of 100 kg for the same year. Calcium 2-ethylhexanoate is used predominantly as an additive in interior and exterior paints. It is also reported to be used in the manufacture of food packaging materials. 2-Ethylhexyl 2-ethylhexanoate is an ingredient in cosmetics.
The ecological risks of calcium 2-ethylhexanoate and 2-ethylhexyl 2-ethylhexanoate were characterized using the ecological risk classification of organic substances (ERC). The ERC is a risk-based approach that employs multiple metrics for both hazard and exposure based on weighted consideration of multiple lines of evidence for determining risk classification. Hazard profiles based primarily on metrics regarding mode of toxic action, chemical reactivity, food web–derived internal toxicity thresholds, bioavailability, and chemical and biological activity are established. Metrics considered in the exposure profiles include potential emission rate, overall persistence, and long-range transport potential. A risk matrix is then used to assign a low, moderate or high level of potential concern for substances based on their hazard and exposure profiles. The ERC identified calcium 2-ethylhexanoate and 2-ethylhexyl 2-ethylhexanoate as having a low potential to cause ecological harm.
Considering all available lines of evidence presented in this screening assessment, there is a low risk of harm to the environment from calcium 2-ethylhexanoate and 2-ethylhexyl 2-ethylhexanoate. It is concluded that calcium 2-ethylhexanoate and 2-ethylhexyl 2-ethylhexanoate do not meet the criteria under paragraph 64(a) or (b) of CEPA, as they are not entering the environment in a quantity or concentration or under conditions that have or may have an immediate or long-term harmful effect on the environment or its biological diversity or that constitute or may constitute a danger to the environment on which life depends.
In Canada, calcium 2-ethylhexanoate may be present in certain food packaging materials. 2-Ethylhexyl 2-ethylhexanoate was reported as a volatile component in a limited number of food samples collected outside of Canada, with very low concentrations. Exposure of the general population to calcium 2-ethylhexanoate and 2-ethylhexyl 2-ethylhexanoate from food is expected to be negligible.
Dermal exposure to calcium 2-ethylhexanoate may occur from the use of interior and exterior household paints, and to 2-ethylhexyl 2-ethylhexanoate from the use of certain cosmetics, including foot lotion and face makeup. Substance-specific health effects data for the relevant route and durations of exposure were not identified. However, 2-ethylhexanoic acid (2-EHA) was selected as an analogue for the characterization of potential health effects of both substances. Laboratory studies of exposure via the oral route identified liver and developmental effects. The margins of exposure between critical effect levels in laboratory studies and the estimates of dermal exposure to calcium 2-ethylhexanoate were considered adequate to address uncertainties in the health effects and exposure databases. The margins of exposure between critical effect levels in laboratory studies and the estimates of dermal exposure to 2-ethylhexyl 2-ethylhexanoate were considered potentially inadequate to address uncertainties in the health effects and exposure databases.
On the basis of available information, it is concluded that calcium 2-ethylhexanoate does not meet the criteria under paragraph 64(c) of CEPA, as it is not entering the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health.
On the basis of available information, it is concluded that 2-ethylhexyl 2-ethylhexanoate meets the criteria under paragraph 64(c) of CEPA, as it is entering or may enter the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health.
It is concluded that calcium 2-ethylhexanoate does not meet any of the criteria set out in section 64 of CEPA and that 2-ethylhexyl 2-ethylhexanoate meets one or more of the criteria set out in section 64 of CEPA.
2-Ethylhexyl 2-ethylhexanoate meets the bioaccumulation criteria but not the persistence criteria as set out in the Persistence and Bioaccumulation Regulations of CEPA.
Because calcium 2-ethylhexanoate is listed on the Domestic Substances List (DSL), its import and manufacture in Canada are not subject to notification under the New Substances Notification Regulations (Chemicals and Polymers) made pursuant to subsection 81(1) of CEPA. Given the hazardous properties of this substance, there is concern that new activities that have not been identified or assessed could lead to this substance meeting the criteria set out in section 64 of the Act. Therefore, the Government of Canada intends to amend the DSL, under subsection 87(3) of the Act, to indicate that the significant new activity (SNAc) provisions under subsection 81(3) of the Act apply with respect to this substance.
The screening assessment for these substances and the risk management approach document for 2-ethylhexyl 2-ethylhexanoate are available on the Canada.ca (Chemical Substances) website.
Whereas a summary of the screening assessment conducted on 19 substances pursuant to paragraphs 68(b) and (c) and on 69 substances pursuant to section 74 of the Act is annexed hereby;
Notice therefore is hereby given that the Minister of the Environment and the Minister of Health (the ministers) propose to take no further action at this time under section 77 of the Act for the 69 substances identified under subsection 73(1) of the Act.
Notice is further given that the ministers propose to take no further action on the remaining 19 substances at this time.
Notice is further given that the Minister of the Environment intends to amend the Domestic Substances List, under subsection 87(3) of the Act, to indicate that subsection 81(3) of the Act applies with respect to 14 substances, as specified in the annexes below.
Summary of the screening assessment of 88 substances specified on the Domestic Substances List
On the basis of available information, 171 substances for which potential for direct exposure to humans was not anticipated were identified and were therefore considered to be candidates for a rapid screening approach. These 171 substances met the categorization criteria under subsection 73(1) of the Canadian Environmental Protection Act, 1999 (CEPA) or were considered a priority because of other human health or ecological concerns.
For this rapid screening analysis, the approach for the human health component has been updated from past rapid screening approaches to incorporate elements of Health Canada’s threshold of toxicological concern (TTC)-based approach. Rather than a volume cut-off based on the commercial status of the substances, a twofold approach was used to determine exposure for the general population of Canada. The initial screening was based on the potential for direct exposure as outlined in previous rapid screening publications. If no direct exposure was identified, rather than using a volume cut-off based on quantities of the substance in commerce, as in most previous rapid screening approaches, the potential for indirect human exposure from environmental media (e.g. air, water, or soil) was determined using an approach based on Health Canada’s TTC approach.
On the basis of this approach, direct and indirect exposure to the general population of Canada is expected to be negligible for 99 of the 171 substances. Direct and/or indirect exposure potential was identified for the remaining 72 substances and, as a result, these substances will undergo further assessment to evaluate risk to human health.
The ecological risks of 89 of the 99 substances identified in this rapid screening assessment as having negligible exposure to the general population were characterized using the ecological risk classification of organic substances (ERC). The ERC is a risk-based approach that employs multiple metrics for assessing both hazard and exposure on the basis of weighted consideration of various lines of evidence to determine risk classification. Hazard profiles are established based primarily on metrics regarding mode of toxic action, chemical reactivity, food web–derived internal toxicity thresholds, bioavailability, and chemical and biological activity. Metrics considered in the exposure profiles include potential emission rate, overall persistence, and long-range transport potential. A risk matrix is used to assign a low, moderate or high level of potential concern for substances on the basis of their hazard and exposure profiles. Three of the 99 substances have previously been determined not to be of ecological concern through rapid screening evaluations. The ecological risks of 7 of the 99 substances remain to be evaluated. As a result of these approaches, 88 of the 99 substances were identified as being of moderate or low ecological concern.
Considering all available lines of evidence presented in this screening assessment, there is a low risk of harm to the environment from the 88 substances listed in Annex II. It is concluded that these 88 substances do not meet the criteria under paragraph 64(a) or (b) of CEPA, as they are not entering the environment in a quantity or concentration or under conditions that have or may have an immediate or long-term harmful effect on the environment or its biological diversity or that constitute or may constitute a danger to the environment on which life depends.
On the basis of the information presented in this screening assessment, it is concluded that these 88 substances listed in Annex II do not meet the criteria under paragraph 64(c) of CEPA, as they are not entering the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health.
It is concluded that the 88 substances identified in Annex II do not meet any of the criteria set out in section 64 of CEPA.
Because the 14 substances specified in Annex II below are listed on the Domestic Substances List (DSL), their import and manufacture in Canada are not subject to notification under the New Substances Notification Regulations (Chemical and Polymers) under subsection 81(1) of CEPA. However, since these 14 substances are considered to have human health effects of concern, there is suspicion that new activities that have not been identified or assessed could lead to these substances meeting the criteria set out in section 64 of CEPA. Therefore, the Government of Canada is proposing to amend the DSL, under subsection 87(3) of the Act, to indicate that the significant new activity (SNAc) provisions under subsection 81(3) of the Act apply with respect to 14 substances, as specified in Annex II below.
A significant new activity can include an activity that is not currently occurring or an existing activity involving a different quantity or occurring in different circumstances that could affect the exposure pattern of the substance. The SNAc provisions trigger an obligation for a person (individual or corporation) to provide, and for the Government to assess, specific information about a substance when a person proposes to use the substance in the proposed new activity. The ministers will assess the information provided by the notifier and other information available to them to determine whether the substance, if used in a significant new activity, could pose a risk to the environment or human health and, if so, whether risk management is required.
74-88-4table 2 note b Methane, iodo-
78-21-7 Morpholinium, 4-ethyl-4-hexadecyl-, ethyl sulfate
91-66-7table 2 note c Benzenamine, N,N-diethyl-
95-54-5table 2 note b 1,2-Benzenediamine
98-88-4table 2 note b Benzoyl chloride
100-00-5table 2 note b,table 2 note c Benzene, 1-chloro-4-nitro-
101-90-6table 2 note b,table 2 note c Oxirane, 2,2′[1,3-phenylenebis(oxymethylene)]bis-
112-90-3 9-Octadecen-1-amine, (Z)-
118-96-7table 2 note b Benzene, 2-methyl-1,3,5-trinitro-
121-14-2table 2 note b,table 2 note c Benzene, 1-methyl-2,4-dinitro-
126-99-8table 2 note b,table 2 note c 1,3-Butadiene, 2-chloro-
271-89-6table 2 note b,table 2 note c Benzofuran
556-52-5table 2 note b,table 2 note c Oxiranemethanol
630-20-6table 2 note b,table 2 note c Ethane, 1,1,1,2-tetrachloro-
632-99-5table 2 note b,table 2 note c Benzenamine, 4-[(4-aminophenyl)(4-imino-2,5-cyclohexadien-1-ylidene)methyl]-2-methyl-, monohydrochloride
647-42-7 1-Octanol, 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-
1533-45-5 Benzoxazole, 2,2′-(1,2-ethenediyldi-4,1-phenylene)bis-
2387-03-3 1-Naphthalenecarboxaldehyde, 2-hydroxy-, [(2-hydroxy-1-naphthalenyl)methylene]hydrazone
2475-45-8table 2 note b,table 2 note c 9,10-Anthracenedione, 1,4,5,8-tetraamino-
2478-20-8 1H-Benz[de]isoquinoline-1,3(2H)-dione, 6-amino-2-(2,4-dimethylphenyl)-
3426-43-5 Benzenesulfonic acid, 2,2′-(1,2-ethenediyl)bis[5-[[4-methoxy-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt
4051-63-2 [1,1′-Bianthracene]-9,9′,10,10′-tetrone, 4,4′-diamino-
4151-51-3 Phenol, 4-isocyanato-, phosphorothioate (3:1) (ester)
4378-61-4 Dibenzo[def,mno]chrysene-6,12-dione, 4,10-dibromo-
5521-31-3table 2 note c Anthra[2,1,9-def:6,5,10-d′e′f′]diisoquinoline-1,3,8,10(2H,9H)-tetrone, 2,9-dimethyl-
5718-26-3 1H-Indole-5-carboxylic acid, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)ethylidene]-2,3-dihydro-1,3,3-trimethyl-, methyl ester
7576-65-0 1H-Indene-1,3(2H)-dione, 2-(3-hydroxy-2-quinolinyl)-
7789-36-8 Bromic acid, magnesium salt, hexahydrate
8021-39-4 Creosote, wood
12068-03-0 Benzenesulfonic acid, methyl-, sodium salt
16294-75-0 14H-Anthra[2,1,9-mna]thioxanthen-14-one
18917-89-0table 2 note c Magnesium, bis(2-hydroxybenzoato-O1,O2)-, (T-4)-
19286-75-0 9,10-Anthracenedione, 1-hydroxy-4-(phenylamino)-
24448-20-2 2-Propenoic acid, 2-methyl-, (1-methylethylidene)bis(4,1-phenyleneoxy-2,1-ethanediyl) ester
25638-17-9table 2 note c Naphthalenesulfonic acid, butyl-, sodium salt
28768-32-3 Oxiranemethanamine, N,N’-(methylenedi-4,1-phenylene)bis[N-(oxiranylmethyl)-
61789-85-3table 2 note c Sulfonic acids, petroleum
62973-79-9 Xanthylium, 9-(2-carboxyphenyl)-3,6-bis(diethylamino)-, molybdatesilicate
63022-09-3 Xanthylium, 9-(2-carboxyphenyl)-3,6-bis(diethylamino)-, molybdatephosphate
66072-38-6 Oxirane, 2,2′,2′′-[methylidynetris
(phenyleneoxymethylene)]tris-
66241-11-0table 2 note c C.I. Leuco Sulphur Black 1
68310-07-6 Xanthylium, 3,6-bis(ethylamino)-9-[2-(methoxycarbonyl)phenyl]-2,7-dimethyl-, molybdatephosphate
68442-82-0table 2 note c Calcium, carbonate dimethylhexanoate complexes
68478-81-9table 2 note c 9-Octadecenoic acid (Z)-, reaction products with 3-(dodecenyl)dihydro-2,5-furandione and triethylenetetramine
68527-02-6table 2 note c Alkenes, C12-24, chloro
68647-55-2 Fatty acids, tall-oil, esters with triethanolamine
68814-02-8 Ethanaminium, N-[4-[bis[4-(diethylamino)phenyl]methylene]-2,5-cyclohexadien-1-ylidene]-N-ethyl-, molybdatephosphate
68890-99-3 Benzene, mono-C10-16-alkyl derivs.
68909-77-3 Ethanol, 2,2′-oxybis-, reaction products with ammonia, morpholine derivs. residues
68952-35-2table 2 note c Tar acids, cresylic, Ph phosphates
68953-80-0table 2 note b,table 2 note c Benzene, mixed with toluene, dealkylation product
68987-42-8 Benzene, ethylenated, residues
70833-37-3 Nickel, bis(3-amino-4,5,6,7-tetrachloro-1H-isoindol-1-one oximato-N2,O1)-
71011-25-1 Quaternary ammonium compounds, benzyl(hydrogenated tallow alkyl)dimethyl, chlorides, compds. with bentonite and bis(hydrogenated tallow alkyl)dimethylammonium chlorides
71820-35-4 Fatty acids, tall-oil, low-boiling, reaction products with 1-piperazineethanamine
75627-12-2 Xanthylium, 3,6-bis(ethylamino)-9-[2-(methoxycarbonyl)phenyl]-2,7-dimethyl-, molybdatesilicate
80083-40-5 Xanthylium, 9-[2-(ethoxycarbonyl)phenyl]-3,6-bis(ethylamino)-2,7-dimethyl-, molybdatetungstatesilicate
90367-27-4 Ethanol, 2,2′-[[3-[(2-hydroxyethyl)amino]propyl]imino]bis-, N-tallow alkyl derivs.
111174-61-9 Alcohols, C8-16, reaction products with phosphorus oxide (P2O5), compds. with 2-ethyl-1-hexanamine
CDSL#10685-2 Substituted dimercaptodithiazole
CDSL#10703-2 Substituted alkylphenol, calcium salt
CDSL#11053-1 Fatty acids compounded with ethylenediamine
CDSL#11555-8 Fatty acids, reaction products with maleic anhydride and triethanolamine
CDSL#11556-0 Fatty acids, reaction products with maleic anhydride
CDSL#11557-1 Fatty acids, reaction products with maleic anhydride and oleylamine
This substance is one of the 14 substances identified to have human health effects of concern.
This notice provides interested stakeholders with the opportunity to provide comments on Health Canada’s intent to amend the following schedules to the Controlled Drugs and Substances Act (CDSA) and its relevant regulations.
Schedule I to the CDSA
Adding “4-Anilino-N-phenethylpiperidine (ANPP) (N-phenyl-1-(2-phenylethyl)piperidine-4-amine), its salts, derivatives, and analogues and salts of derivatives and analogues” as subitem (14) under item 16
Schedule VI to the CDSA
Expanding item 9, Part 1, to include “and its derivatives, and analogues and salts of derivatives and analogues, including:
(1) methyl 3-(1,3-benzodioxol-5-yl)-2-methyloxirane-2-carboxylate (MMDMG)”
Expanding item 11, Part 1, to include “and its derivatives, and analogues and salts of derivatives and analogues, including:
(2) 3-oxo-2-phenylbutanamide (α-phenylacetoacetamide-APAA)”
Expanding item 28, Part 1, to include “and its derivatives, and analogues and salts of derivatives and analogues”
Adding “Benzylfentanyl (N-(1-benzylpiperidin-4-yl)-N-phenylpropionamide), its salts, derivatives, and analogues and salts of derivatives and analogues” as a new item in Part 1
Schedule to the Narcotic Control Regulations (NCR)
Adding “4-Anilino-N-phenethylpiperidine (ANPP) (N-phenyl-1-(2-phenylethyl)piperidine-4-amine), its salts, derivatives, and analogues and salts of derivatives and analogues” as subitem (14) under item 15
Schedule to the Precursor Control Regulations (PCR)
Expanding item 10 to include “and its derivatives, and analogues and salts of derivatives and analogues, including:
Expanding item 13 to include “and its derivatives, and analogues and salts of derivatives and analogues, including:
Expanding item 29 in Column 1 to include “and its derivatives, and analogues and salts of derivatives and analogues”
Adding “Benzylfentanyl (N-(1-benzylpiperidin-4-yl)-N-phenylpropionamide), its salts, derivatives, and analogues and salts of derivatives and analogues” as a new item in Column 1 and indicating “0” in Column 2
Precursors are chemicals that can be used to synthesize controlled substances such as fentanyls and amphetamines, largely occurring in clandestine settings. There are a number of precursors currently controlled under the CDSA and its regulations.
Fentanyls, a group of chemically related substances including fentanyl, are potent synthetic opioid analgesics. The illegal supply of fentanyls has played a key role in the current opioid overdose epidemic in Canada. In order to address the emerging illegal production of fentanyls in Canada, six chemicals that can be used as precursors to illegal manufacturing of fentanyls were added to Schedule VI to the CDSA and to the Schedule to the PCR in 2016 (details can be found in the Canada Gazette, Part II, SOR/2016-295).
In recent years, novel fentanyl analogues have been appearing on the illegal drug market. These substances show psychoactive properties similar to those of fentanyl. While these substances are captured under item 16 in Schedule I to the CDSA, most of their precursors have no legitimate use and are not controlled in Canada. Recently, Canadian law enforcement has intercepted suspicious shipments of these precursors.
Amphetamines, also a group of chemically related substances including amphetamine, methamphetamine and MDMA (Ecstasy), are central nervous system stimulants. While there are approved therapeutic products containing amphetamines, many amphetamines, in particular, methamphetamine and MDMA, have been solely produced for the illegal drug market. Major amphetamine precursors such as ephedrine, pseudoephedrine, phenylacetic acid, and red and white phosphorus are listed in Schedule VI to the CDSA and regulated under the PCR.
In the past few years, the presence of methamphetamine has been on the rise in Canada. Novel precursors for methamphetamine and MDMA have also been identified by law enforcement domestically and internationally.
All fentanyl or amphetamine precursors proposed for scheduling under the CDSA have no legitimate use.
The CDSA and its regulations provide a framework for the control of substances that can alter mental processes and that may result in harm to individuals or to society when diverted to an illegal market or use. The CDSA and its regulations have the dual purpose of protecting public health and maintaining public safety by permitting access to these substances for legitimate industrial, medical or scientific purposes, while mitigating the risk of trafficking and diversion.
Schedule I to the CDSA includes substances that can alter human mental processes and may cause significant harm to public health and safety when used for non-medical purposes. Schedule VI to the CDSA includes chemicals that are essential in the production of controlled substances.
The NCR regulate legitimate activities involving narcotics, including fentanyls. A licence is required for the production, sale/provision, import and export of substances listed in the Schedule to these Regulations, and licensed dealers must comply with requirements outlined in these Regulations, including those with respect to record keeping, security and reporting on loss and theft.
The PCR set out a licensing and permitting framework authorizing regulated parties to conduct activities with precursors under certain circumstances. For example, only licensed dealers can import, export and produce Class A precursors, and a permit is required for individual imports and exports of Class A precursors. Licensed dealers must comply with requirements, including those with respect to record keeping, reporting and security specified in the Regulations.
The Government of Canada is committed to protecting public health and safety from harm caused by problematic substance use by implementing the Canadian Drugs and Substances Strategy, a comprehensive, collaborative, compassionate, and evidence-based approach to drug policy. As part of this approach, the federal government’s regulatory and enforcement activities aim to take a balanced approach, working to reduce the supply of illegal drugs by working to prevent illegal manufacturing, trafficking, and the diversion of substances into the illegal market.
Furthermore, the Government has been taking actions designed to minimize risks associated with opioids. So that legislative control for psychoactive substances can be avoided, fentanyls and amphetamines are altered by small changes to their chemical molecules in a variety of ways. Scheduling these substances under the CDSA regulations would lead to further regulatory controls to support law enforcement in combatting illegal production and distribution of fentanyls and amphetamines in Canada.
The publication of this notice in the Canada Gazette, Part I, initiates a 30-day comment period. Anyone interested in this process or having comments on this notice may contact the Office of Legislative and Regulatory Affairs, Controlled Substances Directorate, Opioid Response Team, Health Canada, by mail at Address Locator: 0302A, 150 Tunney’s Pasture Driveway, Ottawa, Ontario K1A 0K9, or by email at hc.csd.regulatory.policy-politique.reglementaire.dsc.sc@canada.ca.
Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the decisions of the screening officer respecting each claim for exemption and the relevant safety data sheet (SDS) and (where applicable) the label listed below.
In accordance with section 20 of the Hazardous Materials Information Review Act, a claimant or any affected party, as defined, may appeal a decision or order of a screening officer. An affected party may also appeal an undertaking in respect of which a notice has been published in the Canada Gazette. To initiate the appeal process, a Statement of Appeal (Form 1) as prescribed by the Hazardous Materials Information Review Act Appeal Board Procedures Regulations must be completed and delivered, along with the fee prescribed by section 12 of the Hazardous Materials Information Review Regulations, within 45 days of the publication of this notice in the Canada Gazette, Part I, to the Chief Appeals Officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 8th Floor, 4908B, Ottawa, Ontario K1A 0K9.
Transitional provisions allow compliance with either WHMIS 1988 or WHMIS 2015 for a specified period of time. All claims for exemption in this publication were filed and evaluated in accordance with the provisions of WHMIS 2015.
There were no written representations from affected parties with respect to any of the claims for exemption and related SDSs or labels mentioned below.
Each of the claims for exemption listed in the table below were found to be valid except for registry numbers (RNs) 9430, 9626, 9634, and 9635, that were found to be partially valid, and RNs 9093, 9148, 9156, and 9162, that were found to be invalid. The screening officer reached this decision after reviewing the information in support of the claim, having regard exclusively to the criteria found in section 3 of the Hazardous Materials Information Review Regulations.
2017-11-23 Enthone, Inc. ENSTRIP® EN-86B 9148
2017-11-23 Enthone, Inc. ENVISION® CAT-7350A 9156
2017-11-23 Enthone, Inc. Preparation 94X30 9162
2018-01-17 Hach Company Amino Acid F Reagent 9093
2018-01-18 Enthone, Inc. ENPLATE® EN-623C 9143
2018-01-30 Enthone, Inc. ENSTRIP® S 9151
2018-01-23 Canadian Energy Services EnerScav 02 9182
2018-01-23 BWA Water Additives US LLC BELLASOL S65 9430
2018-03-28 LTI Coating Technologies, LLC X-WAX-B 9626
2018-03-28 LTI Coating Technologies, LLC Optical Coating MS-HR800 9634
2018-03-28 LTI Coating Technologies, LLC Optical Coating MS-HR853 9635
2018-08-03 Refine Technologies, Inc. QTRX2 12077
9182 2014-04-26 C.i. of one ingredient C.i. and C. of one ingredient
9430 2015-04-25 C.i. of two ingredients C.i. and C. of one ingredient
9626 2015-11-07 C.i. and C. of three ingredients C.i. and C. of one ingredient
9634 2015-11-07 C.i. and C. of five ingredients
C. of one ingredient C.i. and C. of two ingredients
9635 2015-11-07 C.i. and C. of five ingredients
The claimant name about which the screening officer issued a decision for the following claims is different from the claimant name that was published in the Notice of Filing.
9626 2015-11-07 LTI Coating Technologies, LLC SDC Technologies Inc.
9634 2015-11-07 LTI Coating Technologies, LLC SDC Technologies Inc.
9635 2015-11-07 LTI Coating Technologies, LLC SDC Technologies Inc.
In all cases where the SDS or the label was determined not to be in compliance with the relevant legislation, pursuant to subsection 16.1(1) of the Hazardous Materials Information Review Act, the claimant was given 30 days to provide the screening officer with a signed undertaking accompanied by the SDS or the label amended as necessary.
A description of “administrative non-compliances” and their associated corrective measures are available on Health Canada’s List of Active Claims for Exemption.
Pursuant to paragraph 18(1)(b) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that has been disclosed on the relevant SDS or label in compliance with an undertaking and the date on which the notice referred to in subsection 16.1(3) of the Act was issued.
RN: 12077
Date of compliance undertaking: 2018-08-10
Disclose the following values:
Melting point and freezing point: <0 °C (32 °F)
Boiling range: 65–230 °C
Evaporation rate: 0.04–0.45 (n-butyl acetate = 1)
Upper flammability (explosive) limit: 6.0%
Lower flammability (explosive) limit: 0.7%
Vapour pressure: 0.05–0.5 kPa (0.375–3.75 mm Hg) at 20 °C
Solubility: slightly soluble: 21.5–386.7 mg/L at 25 °C
Partition coefficient — n-octanol/water: Log P(oct) = 2.1–6 (calculated) [typical values for C4-C12 hydrocarbons found in petroleum naphthas]
Auto-ignition temperature: >200 °C at atm. press. of 1.0 atm
Viscosity: kinematic viscosity: 1.33 mm2/s at 20 °C.
Disclose relevant information or indicate “not available” or “not applicable” under the subheading “Hazardous decomposition products”.
Disclose the delayed and chronic effects from long-term exposure to the product.
In the case of the following claims, either the claimant did not supply the screening officer with a signed undertaking or the screening officer was not satisfied that the claimant had taken the measures set out in the undertaking in the manner and within the period specified in it. Pursuant to subsection 17(1) of the Hazardous Materials Information Review Act, the screening officer ordered the claimant to comply with the requirements of the relevant legislation within 30 days from the expiry of the appeal period, except that the information in respect of which the claim for exemption was made does not have to be disclosed, and to provide a copy of the amended SDS to the screening officer within 30 days of expiry of the appeal period.
Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on the SDS reviewed by the screening officer and the date of the order.
RN: 9143 Date of order: 2018-08-15
Disclose the additional hazard classifications of “Skin Corrosion – Category 1” and “Serious Eye Damage – Category 1”.
Disclose the additional information elements including hazard and precautionary statements.
Disclose the actual concentration of the ingredient “Sodium Hydroxide”.
Disclose the applicable common names and synonyms for the ingredient “Sodium Hydroxide”.
Disclose the available or applicable conditions to avoid.
Disclose the calculated product oral ATE of 5 300 mg/kg (2.6% unknown).
RN: 9151 Date of order: 2018-08-15
Disclose the product’s pH, melting point and freezing point, relative density, solubility and auto- ignition temperature.
Disclose the conditions to avoid.
RN: 9182 Date of order: 2018-03-28
The claimant had been advised to amend the SDS (or label) as indicated below.
Disclose the additional hazard classifications of “Reproductive Toxicity – Category 2” and “Specific Target Organ Toxicity – Single Exposure – Category 1”.
Disclose the other hazards known to the supplier with respect to the hazardous product.
Disclose an acceptable concentration range for the ingredient “Ethylene Glycol”.
Disclose the applicable common names and synonyms for “Ethylene Glycol”.
Disclose an “aerosol” notation for the ACGIH exposure limit for the ingredient “Ethylene Glycol”.
Disclose the physical state of the product.
Disclose information on the partition coefficient and viscosity of the product.
Disclose the calculated product oral ATE of 2 200 mg/kg (0% unknown), the dermal ATE of 7 600 mg/kg (0% unknown) and the inhalation (vapour) ATE of 20.1 mg/L (64% unknown).
Resolve the disclosure of misleading information regarding the LD50 (rat, oral) value for the ingredient “Ethylene Glycol”.
Pursuant to section 18 of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on an SDS or a label pursuant to subsection 16(1) and information that has been disclosed on the relevant SDS or label in compliance with an undertaking, and the dates on which the orders and notices referred to in subsection 16.1(3) of the Act were issued.
RN: 9430
Date of compliance undertaking: 2018-02-05
Disclose the hazard classification of “Skin Corrosion – Category 1”.
Disclose an acceptable concentration range for the confidential ingredient “Organic Acid”.
Disclose the method and materials for containment to follow in case of accidental release.
Disclose the product’s vapour density.
Disclose the LD50 (rat, oral) value of 2 870 mg/kg for the confidential ingredient “Organic Acid”.
RN: 9626
Date of compliance undertaking: 2018-06-02
Disclose the other hazards known to the supplier.
Disclose the additional applicable common names and synonyms for the ingredient “Propylene Glycol Butyl Ether”.
Disclose the boiling range, decomposition temperature and viscosity of the product.
Disclose the reactivity hazards of the mixture.
Disclose the calculated product oral ATE of 14 300 mg/kg (0% unknown) and dermal ATE of 62 600 mg/kg (0% unknown).
Disclose the LD50 (rat, oral) value of 1 000 mg/kg for the confidential ingredient “Fatty Alcohols”, the LD50 (rat, oral) value of 2 490 mg/kg and the LD50 (rabbit, dermal) value of 3 130 mg/kg for the ingredient “Propylene Glycol Butyl Ether”.
Disclose the ingredient “Fatty Alcohols” under the subheading “Skin corrosion/irritation”.
Disclose the ingredient “Propylene Glycol Butyl Ether” (CAS RN 5131-66-8) under the subheading “Serious eye damage/ irritation”.
Disclose the subheadings “Specific Target Organ Toxicity – Single Exposure”, “Specific Target Organ Toxicity – Repeated Exposure” and “Aspiration Hazard” with applicable information.
RN: 9634
Disclose the additional hazard classification of “Reproductive Toxicity – Category 2”.
Disclose the additional applicable common names and synonyms for the ingredients “1,6-hexanediol diacrylate (HDODA)”, “n-Propanol” and “Methanol”.
Disclose the symptom “suspected of damaging fertility or the unborn child.”
Disclose the calculated product oral ATE of 3 340 mg/kg (73.2% unknown) and dermal ATE of 5 130 mg/kg (73.2% unknown).
Disclose the LD50 (rabbit, dermal) value of 4 032 mg/kg for the ingredient “n-Propanol”.
Disclose the ingredient “1,6-hexanediol diacrylate” under the subheading “Skin corrosion/irritation”.
Disclose the ingredients “1,6-hexanediol diacrylate” (CAS RN 13048-33-4) and “n-Propanol” under the subheading “Serious eye damage/eye irritation”.
Disclose the ingredient “1,6-hexanediol diacrylate” and the confidential ingredient “Acrylate monomers” under the subheading “Skin sensitization”.
Disclose “Methanol” under the subheading “Reproductive Toxicity”.
RN: 9635
Disclose the symptom “suspected of damaging fertility or the unborn child”.
Disclose the ingredients “1,6-hexanediol diacrylate” (CAS RN 13048-33-4) and “n-Propanol” (CAS RN 71-23-8) under the subheading “Serious eye damage/eye irritation”.
Pursuant to section 18 of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on an SDS or label pursuant to subsection 16(1) and information that has been disclosed on the relevant SDS or label in compliance with an undertaking, and the dates on which the orders and notices referred to in subsection 16.1(3) of the Act were issued.
RN: 9093
Date of compliance undertaking: 2018-02-17
Disclose the additional information elements including precautionary statements.
Disclose other known hazards with respect to the hazardous product.
Disclose the additional applicable common names and synonyms for the ingredient “Sodium Metabisulfite”.
Disclose “exposure to water” as a condition to avoid.
Disclose the calculated product oral ATE of 1 000 mg/kg (0% unknown).
RN: 9148
Date of compliance undertaking: 2018-11-23
The claimant had been advised to correct administrative non-compliances in the SDS (or label).
RN: 9156
RN: 9162
Ottawa, November 22, 2018
Brent D. Salzl
Pursuant to subsection 667(5) of the Criminal Code, I hereby designate the following person of the Saanich Police Department as a fingerprint examiner:
Andrew Patrick Harward
Marie Gilberte Suzanne Gignac
Joseph Henri Marcel-Marie Lebel
Robert Frederick Moyes
WHEREAS pursuant to subparagraph 46(1)(b)(i) of the Act and authorized by way of Order in Council P.C. 1989-24/534 dated March 30, 1989, the Authority wishes to complete a real property exchange with the Canadian National Railway Company.
WHEREAS the board of directors of the Authority has requested that the Minister issue supplementary letters patent amending Schedule B of the letters patent to reflect the said exchange;
1. Schedule B of the letters patent is amended:
006-807-135 Lot 1 District Lot 1992 Range 5 Coast District Plan 8795
008-989-486 Lot A District Lot 1992 Range 5 Coast District Plan 7735
006-807-135 Part of Lot 1, District Lot 1992, Range 5, Coast District, Plan 8795, Except Plan EPP61538
008-989-486 Part of Lot A, District Lot 1992, Range 5, Coast District, Plan 7735, Except Plan EPP61538
2. These supplementary letters patent take effect on the date of registration of the title, in the Prince Rupert Land Title Office, of each parcel of land subject to this exchange.
ISSUED this 29th day of November, 2018.
WHEREAS Schedule C of the letters patent sets out the real property or immovables, other than federal real property or federal immovables, held or occupied by the Authority;
WHEREAS, pursuant to subsection 46(2.1) of the Canada Marine Act (“Act”), the Authority wishes to enter into a Lease and Licence Agreement, as lessee and licensee for a term up to sixty (60) years, with the British Columbia Transportation Financing Authority and the British Columbia Ministry of Transportation and Infrastructure (together, the “Lessor”), whereby the Authority would undertake the construction, operation and maintenance of the Deltaport Truck Staging Facility on the real property described below;
Lease Agreement for use of real property, under the terms and conditions of an agreement concluded July 27, 2018, between the Authority and the Lessor, for a term up to sixty (60) years
A lease on a portion of Highway 17, Right of Way Plan 39429, and Deltaport Way Road, Reference Plan EPP782, District Lots 112 and 113, Group 2, New Westminster District, containing an area of 27 138 m2.
As shown on Lease Plan 2018-052, dated April 11, 2018.
Licence Agreement for use of real property, under the terms and conditions of an agreement concluded July 27, 2018, between the Authority and the Lessor, for a term up to sixty (60) years
A licence on portions of Highway 17, Right of Way Plan 39429, and Deltaport Way Road, Reference Plan EPP782, District Lots 112 and 113, Group 2, New Westminster District, containing a total area of 9 748 m2.
2. These supplementary letters patent take effect on the date of signature of the lease and licence.
ISSUED this 13th day of November, 2018.
Notice is hereby given of the issuance, pursuant to subsection 574(1) of the Insurance Companies Act, of an order authorizing SCOR SE to insure in Canada risks within the classes of life insurance and accident and sickness insurance, effective October 26, 2018.
Supplement, Canada Gazette﻿, Part I, January 31, 1998